Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025

Core Insights - Guardant Health, Inc. announced the presentation of new data from its oncology portfolio in 15 accepted abstracts at the ESMO Congress 2025, scheduled for October 17–21 in Berlin, Germany [1] Group 1: Company Developments - The presentations will cover various aspects of cancer care treatment, including minimal residual disease (MRD) detection, recurrence monitoring, and advanced-stage tumor profiling [1]